中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.028 seconds)

    Lipase variants for pharmaceutical use
    1.
    发明授权
    Lipase variants for pharmaceutical use 有权
    用于药物用途的脂肪酶变体

    公开(公告)号：US09539311B2

    公开(公告)日：2017-01-10

    申请号：US14679563

    申请日：2015-04-06

    Applicant: Novozymes A/S ,  Novozymes Inc.

    Inventor： Allan Svendsen ,  Michael Skjoet ,  Debbie Yaver ,  Lars Lehmann Hylling Christensen ,  Signe Eskildsen Larsen ,  Nina Lundin ,  Michael Lamsa ,  Peter Colin Gregory

    IPC: A61K38/47 ,  A61K38/48 ,  A61K38/54 ,  A61K38/46 ,  C12N9/20 ,  C12N9/14 ,  C12N9/26 ,  C12N9/48 ,  C07H21/04 ,  C07K1/00

    CPC classification number: A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  C12N9/20

    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

    Abstract translation: 与包含SEQ ID NO：2的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。 医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。 本发明的脂肪酶具有例如体外改进的消化性能，在中性范围内的pH值改善的活性，在低pH下的改进的稳定性，对蛋白酶降解是稳定的，和/或在存在时是稳定的 的胃蛋白酶和胆汁盐。 本发明还涉及确定脂肪酶的体外消化性能的方法以及T.lanuginosus的脂肪酶的某些新颖变体。

    Lipase Variants for Pharmaceutical Use
    2.
    发明申请
    Lipase Variants for Pharmaceutical Use 审中-公开
    药用脂肪酶变体

    公开(公告)号：US20150209414A1

    公开(公告)日：2015-07-30

    申请号：US14679563

    申请日：2015-04-06

    Applicant: Novozymes A/S ,  Novozymes Inc.

    Inventor： Allan Svendsen ,  Michael Skjoet ,  Deborah Yaver ,  Lars Lehmann Hylling Christensen ,  Signe Eskildsen Larsen ,  Nina Lundin ,  Michael Lamsa ,  Peter Colin Gregory

    IPC: A61K38/46 ,  A61K38/48 ,  A61K38/47 ,  C12N9/20

    CPC classification number: A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  C12N9/20

    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

    Abstract translation: 与包含SEQ ID NO：2的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。 医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。 本发明的脂肪酶具有例如体外改进的消化性能，在中性范围内的pH值改善的活性，在低pH下的改进的稳定性，对蛋白酶降解是稳定的，和/或在存在时是稳定的 的胃蛋白酶和胆汁盐。 本发明还涉及确定脂肪酶的体外消化性能的方法以及T.lanuginosus的脂肪酶的某些新颖变体。

Patent Agency Ranking